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Induction of apoptosis is one of the main
defenses of the body against cells that
have acquired malicious mutations. It may
seem counter-intuitive then, that massive
cell death is observed in many malignant
tumors (1, 2). Despite high rates of apopto-
sis, these tumors continue to grow rapidly.
Thus, tumor cell growth must outbalance
tumor cell death. Intuitively presumed only
to inhibit tumor growth, apoptotic cells
may actually promote net tumor growth (3,
4). As long ago as 1956, Revesz showed that
cell death can enhance tumor growth (5).
Moreover, new studies in progress in our
laboratory show that apoptosis in tumor
cells promotes growth rates in aggressive
B-cell lymphoma.
Cells undergoing apoptosis are dif-
ficult to observe in vivo, as they are
rapidly cleared by phagocytosis, most obvi-
ously by macrophages. Accumulation of
macrophages, sometimes engorged with
apoptotic cells, is observed in many malig-
nant tumors and is generally associ-
ated with poor prognosis (6, 7). Inflam-
matory cells, in particular macrophages,
are key elements of the tumor environ-
ment, providing support for the con-
tinually expanding “rogue” tissue. The
tumor microenvironment resembles that
of a wound that fails to heal (8), where
macrophages not only clear and repair,
but also promote tissue regeneration and
support. Tumor-associated macrophages
(TAM) display a phenotype that is reminis-
cent of wound-healing macrophages. They
have been shown to promote angiogenesis,
tissue remodeling, and anti-inflammatory
responses, which results in the support of
tumor cell growth and metastasis (9–12).
Apoptosis of tumor cells in a grow-
ing malignant tissue may therefore be
rationalized as a “sinister sacrifice” of
some cancer cells that ultimately facili-
tates cancer progression. We hypothesize
that apoptotic cells play a key role in dri-
ving oncogenesis, both through the release
of soluble and microvesicle-associated sig-
naling factors, as well as through direct
interaction with phagocytes. Here we
postulate lactoferrin (Lf) as an impor-
tant signaling factor maintaining an anti-
inflammatory tumor microenvironment,
and stress the importance of apoptotic
cell engulfment by macrophages for dri-
ving a pro-tumor phenotype in TAM
(Figure 1).
DIRECT EFFECTS OF LACTOFERRIN
Cells undergoing apoptosis release a vari-
ety of biologically active “find-me” or
“keep-out” signaling factors, including the
nucleotides ATP and UTP (13, 14), the lipid
lysophosphatidylcholine (LPC) (15), as
well as the proteins fractalkine (16), Lf (17),
and monocyte chemotactic protein (MCP-
1) (18). Some of these signaling molecules
may be associated with microvesicles, as is
the case with the chemokine, fractalkine
(16), which may support prolonged bio-
logical activity. It has been hypothesized
that these find-me signals not only affect
chemotaxis and phagocytosis, but may
also have additional pleiotropic biologi-
cal effects. Indeed, ATP released by apop-
totic cells increased binding of apoptotic
cells to macrophages (19). Furthermore,
fractalkine has been shown to stimulate
pro-survival and growth-promoting effects
(20, 21) and was found to cause the
expression of milk fat globule epidermal
growth factor (MFG-E8) on macrophages,
which leads to enhanced apoptotic cell
clearance (22).
Lactoferrin was identified in our lab-
oratory to be released from apoptotic
cells. Lf is produced de novo by a diverse
range of cells stimulated to undergo apop-
tosis in vitro (17). This 80 kDa iron-
binding glycoprotein is well-documented
to have immunomodulatory, antimicro-
bial, anti-inflammatory, and trophic activ-
ities (23–26). We propose that Lf is another
pleiotropic molecule released from apop-
totic cells that can regulate the tumor
microenvironment. Thus, since it is well-
known that apoptosis is frequent in sev-
eral types of cancer, particularly high-grade
forms (27), it is conceivable that persistence
of uncleared apoptotic cells (which may
occur through saturation) could enable
these cells to become secondarily necrotic
with the potential consequences of release
of noxious contents via cell lysis leading to
activation of pro-inflammatory responses
(28). However, most malignant tumors
maintain a phenotype that militates against
anti-tumor immune and inflammatory
responses. Given our previous findings that
Lf is released from cells undergoing apop-
tosis (17), together with our unpublished
studies showing that Lf binds to necrotic
cells, we suggest that Lf serves to dampen
down pro-inflammatory responses result-
ing from persistent secondarily necrotic
cells. In fact, it has been shown that
necrotic neutrophil lysates, which contain
large quantities of Lf from the secondary
granules, are anti-inflammatory, and are
able to inhibit the production of pro-
inflammatory cytokines, such as tumor
necrosis factor-α (TNFα), IL6, IL8, and
IL1β, by macrophages (29). The mecha-
nism through which this is achieved may
involve the “mopping up” of necrotic cell-
released pro-inflammatory contents by Lf.
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FIGURE 1 |Tumor cell apoptosis potentially activates multiple oncogenic pathways, promoting
tumor cell growth and survival, angiogenesis, remodeling, and metastasis, while inhibiting
anti-tumor immune responses. We propose that TAM interacting with apoptotic tumor cells are
central to many of these pathways. Apoptotic cells release lactoferrin (Lf) which could promote tumor
growth and progression by: (1) TAM activation, (2) modulating the inflammatory effects of necrosis, (3)
acting as a direct trophic factor, and (4) functioning as a “keep-out” signal to anti-tumor granulocytes.
Lactoferrin has a highly positively
charged N-terminal end (30), which is
capable of interacting with a variety of pro-
teins and membranes, but can also bind a
selection of metal ions as well as iron (31).
Furthermore, Lf can interact with lipid A of
lipopolysaccharide (LPS) causing the neu-
tralization of LPS-stimulated secretion of
pro-inflammatory cytokines by monocytic
cells, including TNFα, IL1β, IL6, and IL8
(32, 33). Mopping of noxious contents by
Lf may be a final safeguard system to pre-
vent pro-inflammatory responses at sites
of high rates of apoptosis. This may not
only help maintain the anti-inflammatory
environment in tumors, but could also play
a role in the resolution of inflammation,
where neutrophil activation and death may
lead to the release of large quantities of
Lf. In addition, in tumors characterized
by neutrophil infiltration, the dominant
source of biologically active Lf may be
derived from neutrophils, rather than
apoptotic tumor cells.
Lactoferrin is also known to directly
exert anti-inflammatory effects by inhibit-
ing the migration of neutrophils (17)
and also by indirectly enhancing the pro-
duction of anti-inflammatory cytokines
including IL4, IL10, and transforming
growth factor-β (TGFβ) (25, 26). Some
studies also suggest that Lf can directly
interact in the nuclear factor κB (NFκB)
pathway interfering with its binding to
DNA (33).
These findings point to a possible
direct mechanism of Lf for control-
ling pro- and anti-inflammatory cytokine
expression. In high-grade malignancies,
these effects of Lf could help moder-
ate anti-tumor inflammatory and immune
responses, allowing continued malignant
growth. The pro-tumor effects of Lf are
likely to be context dependent, however,
since Lf has been shown to have pro-
inflammatory, immunostimulatory, and
cell growth-inhibitory effects (34–36) as
well as anti-inflammatory and trophic
properties. An open, and important ques-
tion is whether Lf is released by dying
tumor cells as a consequence of anti-tumor
therapy and, if so, whether it has properties
which could ultimately confound – or alter-
natively facilitate – long-term therapeutic
efficacy. Again, the significance of Lf may
be tissue context dependent.
EFFECTS OF PHAGOCYTES
INTERACTING WITH APOPTOTIC
TUMOR CELLS
In addition to the release of signaling fac-
tors, interaction of apoptotic cells with
phagocytes also provides opportunities for
regulating tumor cell growth. TAM are
the most important phagocytes of apop-
totic tumor cells in most cancers, and often
prominently display engulfed remnants of
apoptotic cells (2, 37, 38). Current work
in our laboratory indicates that the TAM
of aggressive B-cell lymphoma show up-
regulated expression of receptors involved
in the recognition and engulfment of apop-
totic cells. Furthermore, recent studies in
mice have shown that radiotherapy, one of
the most important anti-cancer treatment
strategies, can enhance tumor cell repop-
ulation in vivo, through the induction of
apoptosis (4). Such effects may be mediated
via responses of macrophages that accumu-
late as a result of the massive radiation-
induced apoptosis as previously proposed
(39). Apart from preventing the build-up
of free apoptotic cells, removal of apoptotic
cells by phagocytosis may therefore drive
the pro-tumor activation status of TAM.
Engulfment of apoptotic cells by
macrophages has been found to acti-
vate downstream signaling pathways that
cause the up-regulation and secretion of
anti-inflammatory mediators such as IL10,
and TGFβ, and the down-regulation of
pro-inflammatory mediators such as IL6,
IL8, IL12, and TNFα (40–43). Further-
more, incubation of phagocytes with apop-
totic cells reduces the effects of LPS,
increasing release of IL10, while reduc-
ing TNFα, IL1β, and IL12 release. Block-
ing apoptotic cell engulfment can prevent
these responses (44). As well as enhancing
anti-inflammatory effects, apoptotic cells
have also been shown to promote tumor
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growth and angiogenesis. Phagocytes can
release growth factors upon engulfment of
apoptotic cells, including VEGF (45), and
apoptotic cells can induce angiogenesis via
electrostatic effects (46).
Given the abilities of apoptotic cells
to induce anti-inflammatory signaling,
angiogenesis, and the release of growth
factors by TAM, it will be important to
determine to what extent they influence
additional pro-tumor macrophage proper-
ties such as matrix remodeling, invasion,
and metastasis.
CONCLUSION
We propose that the apoptotic cell con-
tributes markedly to the conditioning of
the tumor microenvironment. Here, we
suggest that Lf released from apoptotic cells
could contribute to the anti-inflammatory
state of the tumor microenvironment. Fur-
thermore, engagement of apoptotic cells by
macrophages may also inhibit anti-tumor
inflammatory and immune responses, as
well as promote tumor cell growth, angio-
genesis, and tissue remodeling. These nor-
mal, physiological effects of apoptosis
endow this fundamental cell death process
with regulated and homeostatic properties
that permit tissue turnover, organogenesis,
and wound healing. However, these prop-
erties may be hijacked in malignant disease
in order to facilitate cancer progression.
Understanding the complexity of the
signaling of apoptotic tumor cells to viable
tumor cells, macrophages, and other ele-
ments of the tumor environment will be
key to improving tumor treatment out-
comes and to prevent metastasis, by tar-
geting the interaction of the host with
apoptotic cancer cells. This is especially
important since most anti-cancer thera-
pies are designed to induce apoptosis of
malignant cells, which, without inhibi-
tion of these interactions, could ultimately
facilitate tumor repopulation.
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